Buddy Lyons
Contributor since: 2013
BioMarin: Q2 Growth And Tidbits Reinforce Our Investment Thesis
BioMarin: Product Announcements Increase Long-Term Potential And Price Target
Dr. Reddy's: Continues To Stumble. Longer-Term Thesis Intact
Regeneron: A Profitable Opportunity Regardless
Simulations Plus: A Unique Jewel In Computational Biology Offering Compelling Risk-Reward
Dr. Reddy's: Regulatory And Emerging Market Woes Provide Excellent Risk-Reward
BioMarin: Pipeline Disappointments And Negative Sentiment Offer Substantial Long-Term Upside With Limited Risk
A Little Impatience And A Lot Of Skepticism Provides An Excellent Risk-Reward In AcelRx Pharmaceuticals
Simulations Plus: Several Catalysts Provide Favorable Risk-Reward
Momenta: Impending Approval Provides Price Support With Excellent Upside Potential
Tesaro Offers Excellent Risk-Reward: Market Overreacted To Weaker-Than-Expected Data
ISRG: Further To Go Before The Clouds Lift - Short For 50% Gain, Limited Loss Potential
BioMarin: All Drivers Will Soon Be In Place For Explosive Growth - At Least 50% Upside
CareFusion: Increasing ROIC Provides Significant Upside Even With Modest Top-Line Growth
Forest Labs: Let The Good Times Roll - Reward To Risk Still 2:1
Premier Inc.: Healthcare Crisis Creates A Growth Environment
Impax Labs: Beyond The Hayward Debacle, High Reward, Manageable Risk
Forest Labs: Finally Time To Buy Again - Favorably Skewed Risk-Reward In The Next 24 Months
Hospira: Regulatory Woes, Pipeline, And Potential Takeout Offer Asymmetric Multi-Bagger Opportunity